Compare Stocks: SXTC, GLMD, NCNA, and INM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.44	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs
INM InMed Pharmaceuticals	$1.36	$1.39	$0.58 ▼ $2.33	$4.51M	0.93	64,612 shs	28,776 shs
NCNA NuCana	$1.08 -1.8%	$1.36	$0.95 ▼ $6.16	$4.58M	2.3	251,994 shs	28,611 shs
SXTC China SXT Pharmaceuticals	$0.10 -31.4%	$2.95	$0.09 ▼ $83,758.80	$70K	1.86	17.08 million shs	77.75 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLMD Galmed Pharmaceuticals	0.00%	0.00%	0.00%	+6.88%	-59.60%
INM InMed Pharmaceuticals	0.00%	+2.26%	+5.43%	-13.38%	-35.85%
NCNA NuCana	0.00%	+0.92%	-16.67%	-14.06%	-79.36%
SXTC China SXT Pharmaceuticals	0.00%	-93.83%	-94.19%	-99.93%	-100.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLMD Galmed Pharmaceuticals	$4.59 -0.9%	$4.44	$3.29 ▼ $13.20	$4.78M	0.67	52,894 shs	302,067 shs
INM InMed Pharmaceuticals	$1.36	$1.39	$0.58 ▼ $2.33	$4.51M	0.93	64,612 shs	28,776 shs
NCNA NuCana	$1.08 -1.8%	$1.36	$0.95 ▼ $6.16	$4.58M	2.3	251,994 shs	28,611 shs
SXTC China SXT Pharmaceuticals	$0.10 -31.4%	$2.95	$0.09 ▼ $83,758.80	$70K	1.86	17.08 million shs	77.75 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLMD Galmed Pharmaceuticals	0.00%	0.00%	0.00%	+6.88%	-59.60%
INM InMed Pharmaceuticals	0.00%	+2.26%	+5.43%	-13.38%	-35.85%
NCNA NuCana	0.00%	+0.92%	-16.67%	-14.06%	-79.36%
SXTC China SXT Pharmaceuticals	0.00%	-93.83%	-94.19%	-99.93%	-100.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
INM InMed Pharmaceuticals	1.00	Sell	N/A	N/A
NCNA NuCana	1.00	Sell	N/A	N/A
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, GLMD, NCNA, and INM Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/6/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
9/16/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/9/2026	INM InMed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/28/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	NCNA NuCana	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
INM InMed Pharmaceuticals	$4.94M	0.91	N/A	N/A	$0.32 per share	4.25
NCNA NuCana	N/A	N/A	N/A	N/A	$7.71 per share	N/A
SXTC China SXT Pharmaceuticals	$1.14M	0.04	N/A	N/A	$2,468.59 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLMD Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)
INM InMed Pharmaceuticals	-$12.56M	-$1.64	N/A	N/A	N/A	N/A	-156.08%	-123.90%	11/5/2026 (Estimated)
NCNA NuCana	-$38.71M	-$3.81	N/A	N/A	N/A	N/A	-41.90%	-33.69%	11/12/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$6.20M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SXTC, GLMD, NCNA, and INM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q1 2027	INM InMed Pharmaceuticals	-$94.4436	N/A	N/A	N/A	$0.30 million	N/A
9/9/2026	Q4 2026	INM InMed Pharmaceuticals	N/A	-$1.43	N/A	-$1.43	N/A	N/A
9/2/2026	Q2 2026	GLMD Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/13/2026	Q2 2026	NCNA NuCana	-$2.6514	-$0.99	+$1.6614	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLMD Galmed Pharmaceuticals	N/A	4.16	4.16
INM InMed Pharmaceuticals	N/A	1.37	1.37
NCNA NuCana	N/A	4.73	4.73
SXTC China SXT Pharmaceuticals	0.02	7.94	7.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLMD Galmed Pharmaceuticals	76.14%
INM InMed Pharmaceuticals	20.12%
NCNA NuCana	44.00%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
GLMD Galmed Pharmaceuticals	19.80%
INM InMed Pharmaceuticals	0.85%
NCNA NuCana	31.20%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLMD Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
INM InMed Pharmaceuticals	6	3.31 million	3.29 million	Not Optionable
NCNA NuCana	11	4.16 million	2.86 million	Not Optionable
SXTC China SXT Pharmaceuticals	56	480,000	459,000	Not Optionable

SXTC, GLMD, NCNA, and INM Headlines

Recent News About These Companies

Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

October 10 at 7:34 AM | markets.businessinsider.com

China SXT Pharmaceuticals Raises $12 Million in October Registered Direct Offering

October 9 at 5:31 PM | tipranks.com

China SXT Secures $12 Million Financing Through Registered Direct Offering; Stock Down

October 8, 2026 | rttnews.com

China SXT Pharmaceuticals announces $12 million registered direct offering with significant dilution potential

October 8, 2026 | msn.com

China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering

October 8, 2026 | prnewswire.com

China SXT Pharmaceuticals Terminates $3 Million Offshore Share and Warrant Offering

October 8, 2026 | tipranks.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

August 5, 2026 | globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

July 24, 2026 | globenewswire.com

China SXT Pharmaceuticals Raises $9 Million in Registered Direct Offering

July 24, 2026 | tipranks.com

China SXT Pharmaceuticals Enters $9 Million Registered Direct Offering of Units to Institutional Investors

July 23, 2026 | quiverquant.comQ

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

July 23, 2026 | globenewswire.com

China SXT Pharmaceuticals Inc. Cl A

July 14, 2026 | barrons.com

China SXT Pharmaceuticals shares surge over 25% after hours: Here's why

June 2, 2026 | msn.com

China SXT Pharmaceuticals Launches $100 Million ATM Equity Program with Univest Securities

June 1, 2026 | tipranks.com

China SXT Pharmaceuticals Raises $3.5 Million in Offshore Private Placement

May 11, 2026 | theglobeandmail.com

China Sxt Pharmaceuticals, Inc. Class A

April 7, 2026 | edition.cnn.com

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

March 23, 2026 | globenewswire.com

This nano-cap pharma stock crashed 30% today – what triggered the sell-off?

January 30, 2026 | msn.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

January 30, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

January 15, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, GLMD, NCNA, and INM Company Descriptions

Galmed Pharmaceuticals NASDAQ:GLMD

$4.59 -0.04 (-0.86%)

Closing price 09/9/2026

Extended Trading

$4.59 0.00 (0.00%)

As of 09/9/2026 07:56 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

InMed Pharmaceuticals NASDAQ:INM

$1.36 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 +0.00 (+0.37%)

As of 07:30 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

NuCana NASDAQ:NCNA

$1.08 -0.02 (-1.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.09 +0.01 (+1.02%)

As of 07:50 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

China SXT Pharmaceuticals NASDAQ:SXTC

$0.10 -0.05 (-31.41%)

Closing price 04:00 PM Eastern

Extended Trading

$0.09 -0.01 (-10.29%)

As of 08:00 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, GLMD, NCNA, and INM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, GLMD, NCNA, and INM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, GLMD, NCNA, and INM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, GLMD, NCNA, and INM Company Descriptions

Galmed Pharmaceuticals NASDAQ:GLMD

InMed Pharmaceuticals NASDAQ:INM

NuCana NASDAQ:NCNA

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, GLMD, NCNA, and INM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, GLMD, NCNA, and INM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, GLMD, NCNA, and INM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, GLMD, NCNA, and INM Company Descriptions

Galmed Pharmaceuticals NASDAQ:GLMD

InMed Pharmaceuticals NASDAQ:INM

NuCana NASDAQ:NCNA

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools